THE SHORT ANSWER
Does UnitedHealthcare Cover Zepbound?
Coverage Is Not Guaranteed
Whether a UnitedHealthcare commercial plan covers Zepbound for weight loss depends on your employer's plan. Coverage depends heavily on whether your employer specifically opted into weight management benefits. Even when covered, strict prior authorization is required.[1]
UnitedHealthcare (UHC) is the largest health insurer in the United States, but that doesn't mean Zepbound coverage is standard. Here's what you need to know:
- Employer-sponsored plans only cover Zepbound if the employer specifically added weight management drug benefits[1]
- Individual/Marketplace plans typically exclude weight loss medications entirely
- Medicare Advantage does not cover Zepbound for weight loss — see our Medicare coverage guide for details and workarounds[2]
- Optum Rx (UHC's pharmacy benefit manager) places Zepbound in high-cost specialty tiers when covered
Bottom line: Don't assume your UHC plan covers Zepbound. Call the member services number on your insurance card and ask specifically about Zepbound (tirzepatide) coverage for weight management.
For a complete overview of getting Zepbound covered regardless of insurer, see our full coverage guide.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
UHC'S PHARMACY BENEFIT MANAGER
Does OptumRx Cover Zepbound?
OptumRx = UHC's PBM
OptumRx is UnitedHealthcare's pharmacy benefit manager (PBM)—the company that manages prescription drug coverage for UHC plans. If you have UnitedHealthcare insurance, OptumRx handles your medication formulary and prior authorizations.
Does OptumRx cover Zepbound? The answer depends on your specific UHC plan:
- Employer plans with GLP-1 coverage: Yes, OptumRx will process Zepbound with prior authorization
- Employer plans without GLP-1 coverage: No, OptumRx will show "not covered" or "excluded" at the pharmacy
- Individual/Marketplace plans: Rarely covered through OptumRx
- Medicare Part D (via OptumRx): Basic Medicare Part D coverage excludes drugs used for weight loss, but the separate Medicare GLP-1 Bridge (outside Part D) covers the Zepbound KwikPen for $50 per monthly fill (with conditions, including prior authorization) — see Medicare guide
How to Check Your OptumRx Coverage
- Log into OptumRx at optumrx.com or the OptumRx app
- Search for "Zepbound" in the drug lookup/formulary tool
- Check coverage status: It will show "covered with prior auth," "not covered," or "excluded"
- Call Member Services: For detailed questions, call the number on your UHC ID card
Key point: "OptumRx coverage" and "UHC coverage" are the same thing for prescription drugs. OptumRx is simply the entity that processes your UnitedHealthcare pharmacy benefits. All the UHC coverage rules, prior authorization requirements, and appeal processes described on this page apply to OptumRx.
HOW COVERAGE VARIES
UHC Plan Types & Optum Rx Formulary
Your specific UHC plan type significantly affects whether Zepbound might be covered:
| Plan Type | Coverage Likelihood | Notes |
|---|---|---|
| Employer Large Group | Varies widely | Self-funded employers can choose to cover or exclude; ask HR |
| Employer Small Group | Usually excluded | Fully-insured plans rarely cover weight loss drugs |
| Individual/ACA Marketplace | Rarely covered | Most individual plans exclude weight loss medications |
| UHC Medicare Advantage | Not covered | See Medicare guide for details + workarounds[2] |
| UHC Medicaid | State-dependent | Coverage varies by state; most exclude weight loss drugs |
Optum Rx Formulary Placement
Optum Rx is UnitedHealthcare's pharmacy benefit manager (the company that handles prescription coverage). For commercial plans that do cover Zepbound:
- Where it falls on the drug list: Typically not on the standard drug list, or placed in the highest-cost specialty tier
- Prior authorization: Always required—your doctor must get approval before you can fill it
- Cost: Even when covered, expect high out-of-pocket costs due to specialty tier placement
Note: Coverage varies by specific plan. Always check your plan's drug list at uhc.com or by calling member services.
Total Weight Support Program (Employer Plans)
In 2024, UnitedHealthcare launched Total Weight Support—a comprehensive weight loss program exclusively for self-insured employers that bundles GLP-1 medication coverage with coaching and lifestyle support.[10]
What Total Weight Support Includes
- GLP-1 medication coverage (Zepbound, Wegovy) with prior authorization
- Choice of coaching vendors: Real Appeal Rx (live 1:1 or group coaching, pharmacist support) or WeightWatchers for Business (self-directed plans, meal tracking)
- Tools: Smart scales, fitness apps, recipes, and tracking
- Goal: Reduce GLP-1 side effects and discontinuation (30% drop off in the first month without support)
Why it matters: If your employer offers Total Weight Support, you may have better access to Zepbound than standard UHC plans. Ask your HR department if this program is available.
How to Check Your Specific Coverage
Call Script for UHC/Optum
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Zepbound (tirzepatide) covered on my plan for weight management?
- What tier is it on? What would my copay be?
- Is prior authorization required?
- What are the coverage criteria—BMI, required health conditions, anything else?
- Can you send me the coverage policy in writing?"
Pro tip: Always request coverage criteria in writing. Verbal confirmations aren't binding, and having documentation helps if you need to appeal later.
UHC CRITERIA FOR ZEPBOUND
Prior Authorization Requirements
When UHC does cover Zepbound, prior authorization is always required. Key criteria from UHC's official policy (updated September 2025):[3]
- BMI ≥30, or ≥27 with a comorbidity (diabetes, hypertension, sleep apnea, high cholesterol)
- Age over 16 (UHC policy floor; Zepbound itself is FDA-approved for adults only)
- Lifestyle modifications documented (diet, exercise, behavioral support)
- Enrollment in weight management program (e.g., Total Weight Support for employer plans)
- Initial approval: 6 months; Renewals: 12 months (must show ≥5% weight loss)
UHC Does NOT Require Step Therapy
Unlike some insurers, UHC does not require you to try and fail other weight loss medications before Zepbound is approved. You must still meet BMI criteria and show lifestyle modifications.[3]
Faster Approvals: Automated Prior Authorization
As of January 2025, UHC offers automated prior authorization for select GLP-1 medications. Qualifying requests can be approved in as little as 29 seconds to 72 hours—significantly faster than the traditional 1-2 week timeline. Ask your provider to submit electronically for the fastest processing.[9]
For complete prior auth preparation and checklists, see our Zepbound prior authorization guide →
denied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
ALTERNATIVE ROUTE TO COVERAGE
OSA Coverage Pathway
Have Sleep Apnea? You May Have Another Path to Coverage
On December 20, 2024, the FDA approved Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity. Starting July 1, 2025, UHC's sleep apnea policy may cover Zepbound even if your plan excludes weight loss drugs: UHC’s commercial sleep apnea policy (P 1475-3) is Zepbound-only: BMI ≥30 and an AHI, REI or RDI over 15, plus other conditions; 6-month first approval.[4]
If your plan excludes weight loss medications, you may still qualify for Zepbound through the sleep apnea pathway. Be aware: the requirements are stricter than for weight loss coverage. You must meet all of these criteria:
Sleep Apnea Coverage Requirements (All Must Be Met)
- You must be 18 or older
- BMI of 30 or higher
- Sleep study results showing moderate-to-severe sleep apnea (your sleep study score, called AHI or similar, must be greater than 15 events per hour)
- Sleep apnea symptoms—excessive daytime sleepiness, loud snoring, choking/gasping during sleep, or trouble staying asleep
- Tried to lose weight before (at least one documented attempt)
- CPAP machine requirement—you must have either:
- Tried CPAP (used 4+ hours/night, 70%+ of nights) but still have symptoms, OR
- Can't use CPAP for medical reasons
- No diabetes—your A1C (blood sugar test) must be 6.5% or lower
- Sleep specialist involvement—must be prescribed by or in consultation with a sleep specialist
- Received counseling on sleep position and avoiding alcohol/sedatives before bed
- No planned surgeries for sleep apnea or weight loss
- Must be obstructive sleep apnea only—not central or mixed types
To keep coverage: The first approval lasts 6 months. To renew, you'll need at least 10% weight loss from baseline (plus an improved sleep study score if you're not using PAP).
If you have OSA symptoms, ask your doctor about a sleep study. This could open an alternative pathway to Zepbound coverage even if your plan excludes weight loss drugs—but note the criteria are stringent. See our complete OSA coverage guide →
DON'T GIVE UP
If UHC Denies Zepbound
Why Fight for Coverage?
Appeals work: For Medicare Advantage, over 80% of prior auth appeals succeed;[5] for commercial insurance like UHC, success rates are at least 65%+ when properly documented. Winning means you pay just $25/month with Lilly's savings card instead of $499-$1,000+/month without coverage.
If your UHC plan denies Zepbound coverage, here's what to do:
Common UHC Denial Reasons
- "Not medically necessary" — Documentation doesn't support need
- "Does not meet criteria" — BMI or comorbidity requirements not documented
- "Lifestyle modification not documented" — Need diet/exercise records
- "Excluded benefit" — Plan categorically excludes weight loss drugs
What to Do:
Get the Denial in Writing
Request a written denial letter with the specific reason for denial. Note the exact denial code—you'll need this for your appeal.
Identify What's Missing
Compare your documentation to UHC's criteria. Common gaps: BMI not recent, lifestyle attempts not documented, conditions not properly coded.
Gather Additional Evidence
Work with your doctor to address the specific denial reason. Get updated documentation, lab results, or a Letter of Medical Necessity.
File Your Appeal
You have 180 days to appeal. Need help? Use Honest Care to build your appeal →
Alternative Pathways
"Excluded benefit" denial? If your UHC plan categorically excludes weight loss medications, an appeal for medical necessity likely won't succeed. Consider these alternatives:
Have an Employer Plan? Talk to HR
Self-funded employers can modify coverage mid-year. Ask HR to advocate for adding GLP-1 coverage at the next plan renewal.
Open Enrollment
If your plan excludes Zepbound and appeals won't work, open enrollment is your opportunity to switch plans. Verify Zepbound coverage in writing before switching.
Self-Pay Options If UHC Won't Cover
Several affordable alternatives exist:
- TrumpRx.gov: TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price); for Zepbound, the LillyDirect price below (launched February 5, 2026)
- LillyDirect vials: $299–$449/month depending on dose (cash-only)[11]
- Foundayo: Eli Lilly's new oral GLP-1 (FDA approved April 2026) — may have different coverage
LillyDirect pricing: 2.5mg = $299/mo, 5mg = $399/mo, 7.5-15mg = $449/mo. Order at LillyDirect.com.
Just got denied? Start with our Zepbound denied by insurance guide for what to do right now. For complete appeal strategies, see our Zepbound appeals guide →
WHAT'S CHANGING
UHC Coverage Outlook for 2026
Here's what's happening with UHC/OptumRx Zepbound coverage in 2026:
OptumRx Keeping Zepbound on Formulary
Unlike CVS Caremark (where Zepbound was nonpreferred or excluded on some of its most common commercial formularies from July 1, 2025 to September 30, 2026, before returning as an additional preferred option on October 1, 2026), OptumRx kept Zepbound on its 2026 formularies for plans that cover obesity medications. Either way, your own plan's formulary decides coverage.[12]
Medicare Part D: OSA Coverage Now Active
Zepbound may be covered under Part D (including Medicare Advantage drug plans) for the OSA indication, subject to the plan's formulary, prior authorization and exceptions process—but basic Part D still excludes drugs used for weight loss alone. Coverage varies by plan. Requirements: the OSA indication is for adults with obesity (BMI ≥30), with moderate-to-severe OSA confirmed by sleep study, prescribed with diet/exercise. The Part D out-of-pocket cap ($2,100 in 2026 ($2,400 in 2027)) helps control costs.[13]
Separately, the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers the Zepbound KwikPen for weight loss for $50 per monthly fill, with conditions; people with moderate-to-severe OSA aren't eligible for it.
Medicare GLP-1 Bridge for Weight Loss (2026-2027)
The Medicare GLP-1 Bridge is live (July 1, 2026 – December 31, 2027): it runs outside the Part D benefit and covers the Zepbound KwikPen (plus Wegovy and Foundayo) for weight loss for $50 per monthly fill, with conditions, including CMS's BMI criteria and prior authorization. No OSA or diabetes diagnosis is needed; exclusions: Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026. The separate BALANCE model in Part D is Delayed, with no new start date.[13]
Heart Failure Indication (Application Withdrawn)
The SUMMIT trial showed tirzepatide reduced cardiovascular death and serious heart failure events by 38% in patients with obesity and heart failure with preserved ejection fraction (HFpEF).[14] Note: While the trial results were compelling, Eli Lilly withdrew its FDA application for the HFpEF indication in May 2025. This coverage pathway is not currently available.
For UHC Medicare Advantage members, see our complete Medicare coverage guide for detailed 2026 policy updates and workarounds.
UHC ZEPBOUND COVERAGE
Frequently Asked Questions
OptumRx is UnitedHealthcare's pharmacy benefit manager (PBM), so "OptumRx coverage" depends entirely on your UHC plan. If your UHC employer plan covers GLP-1 medications, OptumRx will process Zepbound with prior authorization. If your plan excludes weight loss drugs, OptumRx will show "not covered" at the pharmacy. OptumRx Medicare plans can't cover Zepbound for weight loss themselves, but members can use the Medicare GLP-1 Bridge for the Zepbound KwikPen ($50 per monthly fill, with conditions) — see our Medicare guide. Check your specific coverage at optumrx.com or call the number on your UHC ID card.
It depends on your specific plan. UHC's weight loss coverage is an optional program that employers must elect. Whether your UHC commercial plan covers weight loss drugs depends on whether your employer opted in. Basic Part D coverage in UHC Medicare Advantage plans excludes drugs used for weight loss, but members with drug coverage may be able to use the separate Medicare GLP-1 Bridge (outside Part D; CMS criteria and prior authorization apply) — see our Medicare guide for details. Always call UHC member services to verify your specific coverage.
Per UHC's official policy, requirements include: BMI of 30+, or BMI of 27+ with a weight-related health condition (high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea), over 16 years old, and evidence of lifestyle changes (diet, exercise, behavioral support). Initial approval is for 6 months; to continue, you'll need to show at least 5% weight loss.
No. Unlike some insurers, UHC's official policy does not require you to try and fail other weight loss medications before Zepbound is approved. You must still meet BMI criteria and show you've tried lifestyle changes (diet, exercise, behavioral support).
You have 6 months (180 days) to file an internal appeal. Request the denial in writing with the specific reason, then submit an appeal addressing that reason with supporting documentation. 65%+ of commercial insurance denials are overturned when patients appeal—but fewer than 1 in 10 ever do. If the internal appeal fails, you can request an external review within 4 months—the decision is legally binding on UHC.
Yes, with strict criteria. Since July 1, 2025, UHC's Zepbound sleep apnea policy (now 2026 P 1475-3) covers Zepbound for sleep apnea even when weight loss drugs are excluded. Requirements include: sleep study showing moderate-to-severe sleep apnea, BMI of 30+, failed or can't use CPAP, no diabetes (blood sugar A1C under 6.5%), and involvement of a sleep specialist. Criteria are stricter than weight loss coverage.
With UHC's automated prior authorization (available since January 2025), qualifying electronic submissions can be approved in as little as 29 seconds to 72 hours. For other submissions, most employer plans must decide within within 15 days (72 hours if urgent). Ask your provider to submit electronically for faster processing. Incomplete submissions take longer due to back-and-forth for additional information.
Several alternatives exist: (1) Appeal the denial—65%+ succeed when patients appeal; (2) TrumpRx.gov—lists LillyDirect's self-pay prices (launched Feb 2026); (3) LillyDirect vials—$299–$449/month (cash-only); (4) Foundayo—Eli Lilly's new oral GLP-1 (April 2026); (5) OSA pathway—if you have sleep apnea, coverage may be available; (6) Talk to HR—self-funded employers can modify coverage mid-year.
Yes. Unlike CVS Caremark (where Zepbound was nonpreferred or excluded on some of its most common commercial formularies from July 1, 2025 to September 30, 2026, before returning as an additional preferred option on October 1, 2026), OptumRx kept Zepbound on its 2026 formularies for plans that cover obesity medications. Coverage still requires prior authorization and meeting BMI criteria.
YOUR PATH FORWARD
What's Next
Zepbound Coverage: Other Major Insurers
See how other insurers compare on Zepbound coverage:
- Blue Cross Blue Shield — Major 2026 coverage restrictions announced
- Cigna — Cigna plans may require step therapy; check your plan’s policy
- Aetna — Most plans exclude; limited employer exceptions with PA
- Anthem Blue Cross — Separate policies from other BCBS affiliates
- Humana — Coverage varies; Medicare Advantage options
Other GLP-1 Medications at UnitedHealthcare
UnitedHealthcare's coverage varies by medication. Compare your options:
References
- SingleCare. (2025). "Does United Healthcare cover Zepbound?" singlecare.com; See also: NiceRx. (2024). "Does United Healthcare cover Zepbound?" nicerx.com
- Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 42 U.S.C. § 1395w-102(e)(2)(A)(ii); CMS. "Excluded Drug Reference File FAQ." cms.gov (PDF); KFF. (2024). "A New Use for Wegovy Opens the Door to Medicare Coverage." kff.org; AARP. (2025). "Does Medicare Cover Ozempic and Other Weight Loss Drugs?" aarp.org
- UnitedHealthcare. (2025). "Plans with Weight Loss/Appetite Suppression Medication Coverage: Prior Authorization Notification." Policy updated September 2025. uhcprovider.com (PDF); Eli Lilly. "Zepbound Prior Authorization Resource Guide." zepbound.lilly.com (PDF)
- UnitedHealthcare. (2025). "Zepbound® (tirzepatide) – Obstructive Sleep Apnea Only: Prior Authorization." Policy 2026 P 1475-3 (first effective July 1, 2025). uhcprovider.com (PDF)
- KFF. (2025). "Medicare Advantage Insurers Made Nearly 50 Million Prior Authorization Determinations in 2023." 81.7% overturn rate, 11.7% appeal rate. kff.org; AMA. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org
- Jastreboff AM, et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. SURMOUNT-1 trial showing 15-21% weight loss. PubMed
- HealthCare.gov. "External Review." Your right to request an independent review of insurance denials. healthcare.gov; See also: "Internal Appeals." healthcare.gov
- FDA. (December 20, 2024). "FDA Approves First Medication for Obstructive Sleep Apnea." fda.gov; Eli Lilly. (December 2024). "FDA approves Zepbound for moderate-to-severe OSA." investor.lilly.com
- UnitedHealthcare. (2025). "Automated Prior Authorization for GLP-1 Medications." Electronic submissions can be processed in 29 seconds to 72 hours as of January 2025. uhcprovider.com
- UnitedHealthcare. (2024). "Total Weight Support Program." Comprehensive weight loss program for self-insured employers combining GLP-1 coverage with Real Appeal Rx or WeightWatchers for Business coaching. uhc.com; See also: Healthcare Dive. (2024). "UnitedHealthcare launches Total Weight Support for employers."
- Eli Lilly. (2024-2026). "Zepbound Single-Dose Vials." Available through LillyDirect at $299-$449/month for self-pay patients. lillydirect.com; Walmart pickup available.
- OptumRx. (2025). "2026 Premium Formulary Booklet." Zepbound listed for weight management coverage. optumrx.com (PDF)
- CMS. (2025). "Medicare Part D Coverage for GLP-1 Medications." Part D out-of-pocket cap ($2,000 in 2025; $2,100 in 2026); OSA indication may be covered, subject to plan formulary and prior authorization; Medicare GLP-1 Bridge (outside Part D) for weight loss July 1, 2026 – December 31, 2027. cms.gov; Eli Lilly announced price reductions for Medicare/Medicaid starting 2026.
- Eli Lilly. (2024). "SUMMIT Trial Results: Tirzepatide for Heart Failure." 38% reduction in cardiovascular death and heart failure events in patients with obesity and HFpEF. investor.lilly.com; FDA application withdrawn May 2025.
- CVS Caremark. (2025). "Formulary Updates: Zepbound Removal." Zepbound nonpreferred or excluded on some commercial template formularies effective July 1, 2025, with Wegovy preferred (Zepbound added back as an additional preferred option October 1, 2026). caremark.com
- UnitedHealthcare. (2025). "Plans with Weight Loss/Appetite Suppression Medication Coverage." Weight-loss program criteria (the separate OSA policy, P 1475-3, gives a 6-month initial approval). uhcprovider.com (PDF)
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.